Zenas BioPharma to present Phase 3 INDIGO open-label extension data on obexelimab in IgG4-related disease at IgG4ward symposium
ZBIO•Planned presentations at IgG4ward symposium and ACR Convergence 2026
Zenas Biopharma scheduled new Phase 3 INDIGO obexelimab updates in IgG4-related disease for October 8-10, 2026, then ACR Convergence 2026.
- Results will be presented in the future, including longer-term flare protection and safety from the INDIGO open-label extension.
- Separate analyses are set to show reduced glucocorticoid-associated toxicity in the randomized, placebo-controlled INDIGO trial.
- Another presentation will address whether patients maintained clinically meaningful influenza and SARS‑CoV‑2 vaccine responses during a treatment-free window.
